What Is Food Noise? Appetite Changes on GLP-1

Food noise is the persistent, intrusive preoccupation with food — unwanted thoughts about eating that go beyond normal hunger. A survey by the STOP Obesity Alliance found that approximately 57% of individuals living with overweight or obesity experience these continuous, disruptive thoughts about food. GLP-1 medications like Ozempic® (semaglutide), Wegovy® (semaglutide), and Mounjaro® (tirzepatide) have been shown to significantly reduce food noise by acting on appetite-regulating pathways in the brain.

What exactly is food noise?

Food noise refers to repetitive, unwanted mental preoccupation with food that feels difficult to control. It is not the same as normal hunger or casually thinking about what to have for dinner. A 2023 conceptual model published in Nutrients described food noise as a form of heightened food-cue reactivity — the brain's exaggerated response to food-related stimuli such as images, smells, or even the thought of eating.

A 2025 paper in Nutrition & Diabetes formally defined food noise as "persistent thoughts about food that are perceived by the individual as being unwanted and/or dysphoric and may cause harm to the individual, including social, mental, or physical problems." This distinguishes food noise from routine meal planning or enjoyment of food by its intensity, intrusiveness, and negative impact on daily life.

People who experience food noise often describe it as a constant mental loop — thinking about the next meal while still eating, struggling to concentrate at work because of food thoughts, or feeling unable to stop planning what to eat even when they are not hungry. In the STOP Obesity Alliance survey, 65% of respondents reported regularly fighting the urge to eat despite not being physically hungry, and 61% said food noise interfered with their ability to follow nutrition or exercise plans.

What causes food noise?

Food noise appears to involve the brain's reward circuitry, particularly the dopamine-driven mesolimbic pathway that responds to highly palatable foods — those high in sugar, fat, and salt. In people with overweight or obesity, this reward system can become hypersensitive, causing food cues to trigger stronger-than-normal cravings and preoccupation.

A 2025 narrative review published in the Journal of Education, Health and Sport explained that food noise is best understood as a form of maladaptive prospection — the brain repeatedly simulating short-term food reward scenarios that conflict with long-term health goals. This is different from physiological hunger, which is driven by hormones like ghrelin signaling an actual need for calories.

Additional contributing factors may include chronic dieting and restriction (which can heighten food preoccupation), sleep deprivation, stress, and individual differences in brain reward sensitivity. Not everyone with a higher body weight experiences food noise, and not everyone who experiences food noise has obesity — but the overlap is significant.

How do GLP-1 medications reduce food noise?

GLP-1 receptor agonists like semaglutide and tirzepatide reduce food noise through multiple pathways. According to the FDA prescribing information for Wegovy, semaglutide "lowers body weight through decreased calorie intake" with effects "likely mediated by affecting appetite," and animal studies confirmed that semaglutide activates neurons in brain regions involved in food intake regulation.

Research presented at the 2025 European Association for the Study of Diabetes (EASD) Annual Meeting found a sharp reduction in food noise among patients taking GLP-1 medications. A preliminary 2026 study published in the Proceedings of the National Academy of Sciences suggested that GLP-1 medications may also influence the brain's default mode network (DMN), the neural system associated with mind-wandering and rumination — potentially explaining why intrusive food thoughts decrease.

For tirzepatide specifically, a randomized phase 1 trial published in Nature Medicine in 2025 showed that participants taking tirzepatide exhibited reduced activity in hunger- and reward-sensitive brain areas when viewing images of high-fat, high-sugar foods. Tirzepatide reduced energy intake by approximately 525 kcal per day compared to placebo by week 3, and significantly decreased 10 of 12 food preference scores and 4 of 6 food craving scores.

In simpler terms: these medications appear to turn down the volume on the brain's food reward signals, making hyperpalatable foods feel less compelling and allowing people to make food choices based on actual hunger rather than compulsive craving.

What does the clinical trial data show about appetite changes?

The STEP 5 trial — a two-year study of semaglutide 2.4 mg — measured appetite changes using the Control of Eating Questionnaire. Participants on semaglutide reported significantly improved scores for craving control, hunger and fullness, and difficulty resisting cravings compared to placebo. These improvements were sustained over 104 weeks of treatment and were associated with approximately 15% body weight loss.

A separate pharmacology study found that semaglutide 2.4 mg led to a 35% reduction in energy intake during an ad libitum lunch at week 20 compared to placebo, along with a 24% reduction in total daily energy intake. Participants also reported less hunger, fewer food cravings, and a lower preference for high-fat foods.

A survey of 411 adults taking semaglutide or tirzepatide found additional sensory changes: approximately 21% reported food tasting sweeter and 23% reported food tasting saltier since starting medication. These taste perception changes were associated with earlier satiety, reduced appetite, and fewer food cravings — suggesting that GLP-1 medications may alter the sensory experience of eating as well as the cognitive experience.

Is the reduction in food noise permanent?

Current evidence suggests that the reduction in food noise depends on continued medication use. A 2025 case study published in Nature Medicine tracked brain activity in a patient on tirzepatide and found that while the medication suppressed food-related signaling in the brain's reward center, this effect was temporary — food preoccupation returned during periods of breakthrough cravings, even while on active treatment.

Data from the STEP 1 trial extension showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year, suggesting that appetite suppression and the associated quieting of food noise may reverse after stopping medication. However, long-term studies specifically measuring food noise persistence after discontinuation are still limited.

This is an important consideration when building sustainable eating habits during GLP-1 treatment. Many healthcare providers recommend using the period of reduced food noise as an opportunity to develop new routines around nutrition, portion sizes, and eating behaviors that may be easier to maintain long term.

How can you tell if you are experiencing food noise?

Food noise can be difficult to recognize because persistent food thoughts often feel normal to the person experiencing them — especially if they have been present for years. A validated Food Noise Questionnaire was developed and published in Obesity in 2025, providing a standardized way to measure the experience.

Common signs include: thinking about food even when you just finished eating, difficulty concentrating on tasks because of food-related thoughts, feeling driven to eat even when you know you are not physically hungry, spending significant mental energy planning meals or resisting cravings, and feeling that food thoughts interfere with social activities or work.

In the STOP Obesity Alliance survey, only 12% of people who experienced food noise were familiar with the term itself. This means many people live with the experience without having language for it, which can make it harder to discuss with a healthcare provider. If these descriptions sound familiar, it may be worth raising the topic at your next appointment.

How can tracking help with food noise awareness?

One practical benefit of tracking your GLP-1 routine is that it creates a record of how your appetite and food thoughts change over time. Many people notice a significant shift in food noise within the first few weeks of starting medication or after a dose increase, but without tracking, these changes can be hard to pinpoint.

Glone's symptom tracking features allow you to log appetite changes alongside your injection schedule, making it easier to identify patterns — such as whether food noise decreases after dose escalation or returns at the end of your dosing interval. This kind of data can also be useful in conversations with your healthcare provider about whether your current dose is effective.

Keeping a brief daily note about food noise intensity — even a simple scale from 1 to 10 — can help you and your provider make more informed decisions about managing side effects and optimizing your treatment plan.

What should you discuss with your healthcare provider?

If you experience significant food noise, it is worth discussing with your healthcare provider for several reasons. First, the severity of food noise may influence which medication or dose is most appropriate for you. Second, persistent food preoccupation can sometimes overlap with disordered eating patterns that may benefit from additional support, such as counseling with a therapist who specializes in eating behavior.

Your provider can help you distinguish between normal appetite changes on GLP-1 medication and food noise that may require additional intervention. They can also help monitor for the opposite extreme — some patients on higher doses experience such a dramatic reduction in appetite that they struggle to eat enough to meet basic nutritional needs, particularly for protein and essential micronutrients.

If you notice that food noise returns significantly between doses or after a dose reduction, this is important information to share. It may indicate that your current dose is not fully managing appetite-related symptoms, and your provider may recommend adjustments.

Sources

• STOP Obesity Alliance — Understanding Food Noise Survey — stop.publichealth.gwu.edu
• Espel-Huynh et al. — What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023), Nutrients — pmc.ncbi.nlm.nih.gov
• Diktas et al. — Food noise: definition, measurement, and future research directions (2025), Nutrition & Diabetes — nature.com
• FDA Prescribing Information for Wegovy (semaglutide) — accessdata.fda.gov
• Wharton et al. — Two-year effect of semaglutide 2.4 mg on control of eating: STEP 5 (2023), Obesity — onlinelibrary.wiley.com
• Blundell et al. — Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity (2017), Diabetes, Obesity and Metabolism — pmc.ncbi.nlm.nih.gov
• Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial (2025), Nature Medicine — nature.com
• Brain activity associated with breakthrough food preoccupation on tirzepatide (2025), Nature Medicine — nature.com
• Diktas et al. — Development and validation of the Food Noise Questionnaire (2025), Obesity — onlinelibrary.wiley.com